REGN Q4 2024 Earnings — Regeneron Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

REGNRegeneron Pharmaceuticals, Inc.

$81B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$3.8B+10.3% YoY

Gross Profit

$3.2B85.1% margin

Operating Income

$990M26.1% margin

Net Income

$918M24.2% margin

EPS (Diluted)

$8.06

QoQ Revenue Growth

+1.8%

Cash Flow

Operating Cash Flow

$1.3B

Free Cash Flow

$996M

Stock-Based Comp.

$304M

Balance Sheet

Total Assets

$37.8B

Total Liabilities

$8.4B

Stockholders' Equity

$29.4B

Cash & Equivalents

$2.5B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$3.8B	$3.4B	+10.3%
Gross Profit	$3.2B	$2.8B	+14.9%
Operating Income	$990M	$1.1B	-5.8%
Net Income	$918M	$1.2B	-20.9%

Revenue Segments

Product

$2.0B53%

Collaboration Revenue

$1.6B42%

Product and Service, Other

$179M5%